Jim Cramer: Lemonade Is 'Up Too Much,' This Health Care Stock Can Go Lower
Jim Cramer: Lemonade Is 'Up Too Much,' This Health Care Stock Can Go Lower
On Jan. 2, Cencora announced the completion of its previously announced acquisition of Retina Consultants of America, a leading management services organization of retina specialists.On CNBC's "Mad Money Lightning Round," Jim Cramer said Lemonade, Inc. (NYSE:LMND) is "up too much... You got to let it come down."
在CNBC的“疯狂金钱快闪环节”中，吉姆·克雷默表示Lemonade, Inc. (纽交所：LMND)的股价"涨得太多了... 你得等它回落。"
On Nov. 22, JMP Securities analyst Ronald Josey maintained Lemonade with a Market Outperform and raised the price target from $40 to $60.
在11月22日，JMP Securities分析师罗纳德·霍西保持了对Lemonade的市场优于大盘评级，并将目标股价从40美元上调至60美元。
Cencora, Inc. (NYSE:COR) can go lower and he prefers Cardinal Health, Inc. (NYSE:CAH) to it.
Cencora, Inc. (纽交所：COR)的股价可能会下跌，他更喜欢卡地纳健康公司(纽交所：CAH)。
On Jan. 2, Cencora announced the completion of its previously announced acquisition of Retina Consultants of America, a leading management services organization of retina specialists.
1月2日，Cencora宣布完成其先前公布的对美国视网膜专家管理服务组织Retina Consultants的收购。
Cramer said he would be "careful" with Novo Nordisk A/S (NYSE:NVO).
克雷默表示，他会对诺和诺德A/S(纽交所：NVO)"谨慎"。
On Dec. 20, Novo Nordisk released headline results from the REDEFINE 1 Phase 3 trial in the global REDEFINE program. REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual components cagrilintide 2.4 mg, semaglutide 2.4 mg, and placebo, all administered once-weekly.
在12月20日，诺和诺德发布了全球REDEFINE项目的REDEFINE 1 III期试验的主要结果。REDEFINE 1是一个68周的有效性和安全性试验，研究皮下CagriSema（cagrilintide 2.4毫克和semaglutide 2.4毫克的固定剂量组合）与单独的元件cagrilintide 2.4毫克、semaglutide 2.4毫克和安慰剂的比较，所有药物均每周给药一次。
PepsiCo (NASDAQ:PEP) right now, is in the "crosshairs of the GLP-1 situation," Cramer said.
克雷默表示，百事可乐（纳斯达克：PEP）目前正处于"GLP-1局势的瞄准之中"。
On Jan. 7, Piper Sandler analyst Mike Lavery initiated coverage on PepsiCo with an Overweight rating and announced a price target of $171.
1月7日，派杰投资分析师迈克·拉弗里开始对百事可乐的覆盖，给予了超配评级，并宣布了171美元的目标股价。
Price Action:
价格行动：
- Novo Nordisk shares fell 2% to settle at $83.34 on Tuesday.
- PepsiCo shares fell 0.6% to close at $145.40 during the session.
- Cencora shares gained 2.3% to settle at $234.24.
- Lemonade shares fell 6.3% to settle at $36.14 on Tuesday.
- 诺和诺德的股票周二下跌2%，收于83.34美元。
- 百事可乐的股票在交易中下跌0.6%，收于145.40美元。
- Cencora的股票上涨2.3%，收至234.24美元。
- Lemonade的股票周二下跌6.3%，收于36.14美元。
- Bank of New York Mellon Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
- 纽约梅隆银行业绩即将公布；这些最准确的分析师在业绩会前修订了预测
Image: Shutterstock
图片：shutterstock
